Skip to search formSkip to main contentSkip to account menu
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
TLDR
Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy and is supported by the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
View on PubMed
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial
TLDR
In this first clinical study to date of intranasal esketamine for TRD, antidepressant effect was rapid in onset and dose related and response appeared to persist for more than 2 months with a lower dosing frequency.
View on Wolters Kluwer
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
OBJECTIVE Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated…
View on PubMed
Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder
TLDR
Bavisant is a highly selective, orally active antagonist of the human H3 receptor with a novel mechanism of action, involving wakefulness and cognition, with potential as a treatment for ADHD.
View on Springer
Intranasal esketamine in treatment resistant depression – a double-blind, randomized, efficacy and dose response study
View via Publisher
S111. Randomized, Double-Blind Study of Flexibly-Dosed Intranasal Esketamine Plus Oral Antidepressant Vs. Active Control in Treatment-Resistant Depression
View on Elsevier
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind,…
TLDR
Objective evaluation of nasal function showed no evidence of an adverse impact following esketamine administration, and Esketamine nasal spray was well tolerated, as indicated by responses on the NSQ and negative nasal examination findings.
View on Springer
Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.
View on PubMed
Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant…
View on PubMed
Dietary outcomes within the study of novel approaches to weight gain prevention (SNAP) randomized controlled trial
TLDR
The need to strengthen interventions to produce longer term changes in dietary intake and helps to identify specific behaviors associated with weight gain over time in young adults is suggested.
View on Springer
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License